VRCA beat EPS expectations by 95.64%
Nov 16, 2025, 11:35 AM
0.00%
What does VRCA do
Verrica Pharmaceuticals, headquartered in West Chester, Pennsylvania, develops treatments for skin diseases and went public in June 2018. Its pipeline includes YCANTH, VP-315, and VP-103 for various skin conditions.
Verrica Pharmaceuticals (VRCA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Verrica Pharmaceuticals's actual EPS was -$0.03, beating the estimate of -$0.69 per share, resulting in a 95.64% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.